Finance entity
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Cipla, the most common co-covered peer. At 8, the average consequence score sits above the same-window beat average of 6.3.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Cipla, the most common co-covered peer. At 8, the average consequence score sits above the same-window beat average of 6.3. Each story carries 3 original sources on average, compared with 2.6 for the broader beat in this window. We currently track 1 Finance story that mention Dr. Reddy's Laboratories, all published on March 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 84 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Reddy's Laboratories. Shared-story counts are live from our verified record — not editorial picks.
India's pharmaceutical sector has launched a massive rollout of affordable versions of popular weight-loss medications, targeting the global dominance of high-priced GLP-1 agonists. This move threatens the premium pricing models of Western pharmaceutical giants while significantly expanding patient access in price-sensitive emerging markets.
Dr. Reddy's Laboratories is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
